China SXT Pharmaceuticals
SXTC
10 hedge funds and large institutions have $491K invested in China SXT Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and closing their positions.
270% more capital invested
Capital invested by funds: $133K → $491K (+$358K)
233% more funds holding
Funds holding: 3 → 10 (+7)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$148K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$88.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$80.3K |
| 4 |
Renaissance Technologies
New York
|
+$73.3K |
| 5 |
HF
HRT Financial
New York
|
+$44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$103K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Invesco
Atlanta,
Georgia
| $141K | +$148K | +598 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $85.3K | +$88.4K | +358 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $77.5K | +$80.3K | +325 | New |
|
|
4
Renaissance Technologies
New York
| $69.9K | +$73.3K | +297 | New |
|
|
VF
5
Virtu Financial
New York
| $46K | +$24.7K | +100 | +108% |
|
|
HF
6
HRT Financial
New York
| $42K | +$44K | +178 | New |
|
|
TSS
7
Two Sigma Securities
New York
| $24.3K | +$25.4K | +103 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $4.52K | +$4.45K | +18 | +1,800% |
|
|
9
UBS Group
Zurich,
Switzerland
| $157 | -$103K | -416 | -100% |
|
|
SOW
10
State of Wyoming
Cheyenne,
Wyoming
| $142 | +$247 | +1 | New |
|
SXTC Hedge Fund Activity: Q3 2025 in Review
10 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q3 2025, worth a combined $491K — up 270% from $133K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SXTC positions and 0 closed out — a net gain of 7 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $148K. The largest seller was UBS Group, cutting an estimated $103K.
- 10 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q3 2025, up from 3 in Q2 2025.
- Funds reported $491K of China SXT Pharmaceuticals stock for Q3 2025, up 270% quarter-over-quarter.
- 7 funds opened new China SXT Pharmaceuticals positions in Q3 2025 and 0 closed out, a net change of +7 holders.
- The largest China SXT Pharmaceuticals buyer in Q3 2025 was Invesco, an estimated $148K added.
- The largest China SXT Pharmaceuticals seller in Q3 2025 was UBS Group, an estimated $103K sold.
Based on aggregated 13F filings for Q3 2025.